NEW YORK (GenomeWeb News) — Ariadne yesterday said that Bayer HealthCare has renewed and expanded a licensing agreement that allows it to use the company’s Pathway Studio through 2010 for toxicology studies and microarray data analysis.
The Ariadne data-mining software is used to analyze pathways, signaling networks, and to interpret microarray data, the company said.
Ariadne also said it is developing a MedScan toxicology module that holds knowledge of small molecules and their interactions with cells and proteins, which Bayer HealthCare will use in its research.
Financial terms of the agreement were not released.